Last updated on October 2020

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)


Brief description of study

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

Detailed Study Description

This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

Clinical Study Identifier: NCT04374136

Find a site near you

Start Over

Dignity Health

Phoenix, AZ United States
  Connect »

University of Colorado

Aurora, CO United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Northwestern University

Evanston, IL United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Hospital Universitario de Donostia

Donostia-san Sebastián, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.